Get started
Alzamend Neuro, Inc.Alzamend Neuro, Inc.Alzamend Neuro, Inc.

Alzamend Neuro, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonals
Full chart
Full chart

Compare with Alzamend Neuro, Inc.



Key stats


Market capitalization
‪7.43 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.90 USD
Net income (FY)
‪−8.77 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪4.02 M‬
Beta (1Y)
3.24

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
6
Change (1Y)
−1−14.29%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.46 M‬ USD

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Stephan Jackman
Website
alzamend.com
Headquarters
Atlanta
Founded
2016
IPO date
Jun 15, 2021
ISIN
US02262M6057
CUSIP
02262M605
FIGI
BBG00ZMXG7M8
Identifiers
ISIN US02262M6057
CFI code
ESVTFR
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently asked questions


The current price of ALZN is 1.58 USD — it has increased by 6.16% in the past 24 hours. Watch Alzamend Neuro, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alzamend Neuro, Inc. stocks are traded under the ticker ALZN.
ALZN stock has risen by 12.32% compared to the previous week, the month change is a 29.17% rise, over the last year Alzamend Neuro, Inc. has showed a −33.56% decrease.
ALZN reached its all-time high on Jun 15, 2021 with the price of 45,292.50 USD, and its all-time low was 0.84 USD and was reached on Apr 13, 2026. View more price dynamics on ALZN chart.
See other stocks reaching their highest and lowest prices.
ALZN stock is 7.38% volatile and has beta coefficient of 3.24. Track Alzamend Neuro, Inc. stock price on the chart and check out the list of the most volatile stocks — is Alzamend Neuro, Inc. there?
Today Alzamend Neuro, Inc. has the market capitalization of ‪7.43 M‬, it has decreased by −2.96% over the last week.
Yes, you can track Alzamend Neuro, Inc. financials in yearly and quarterly reports right on TradingView.
Alzamend Neuro, Inc. is going to release the next earnings report on Sep 15, 2026. Keep track of upcoming events with our Earnings Calendar.
ALZN net income for the last quarter is ‪−2.87 M‬ USD, while the quarter before that showed ‪−2.20 M‬ USD of net income which accounts for 0.00% change. Track more Alzamend Neuro, Inc. financial stats to get the full picture.
No, ALZN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 17, 2026, the company has 6 employees. See our rating of the largest employees — is Alzamend Neuro, Inc. on this list?
Like other stocks, ALZN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alzamend Neuro, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alzamend Neuro, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alzamend Neuro, Inc. stock shows the sell signal. See more of Alzamend Neuro, Inc. technicals for a more comprehensive analysis.